First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer [0.03%]
用于ER+/HER2-晚期乳腺癌患者一线治疗的CAMZISELECTIN抑制剂
François-Clément Bidard,Erica L Mayer,Yeon Hee Park et al.
François-Clément Bidard et al.
Background: Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer. Camizestran...
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer [0.03%]
用于治疗乳腺癌内分泌治疗后血管舒缩症状的elinzanetant
Fatima Cardoso,Susanne Parke,Donal J Brennan et al.
Fatima Cardoso et al.
Background: Women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its prevention among those at high risk for breast cancer commonly have vasomotor symptoms. Data are lacking on the effects...
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer [0.03%]
胃癌患者中注射曲妥珠单抗德鲁昔玛与Ramucirumab加顺铂的疗效比较试验
Kohei Shitara,Eric Van Cutsem,Mahmut Gümüş et al.
Kohei Shitara et al.
Background: On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric cancer or gastroesophageal junction adenocarci...
Habib A Dakik
Habib A Dakik
Kerry S Courneya,Janette L Vardy,Christopher J O&#x;Callaghan et al.
Kerry S Courneya et al.
Background: Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. Meth...
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer [0.03%]
用于BRAF基因突变结直肠癌患者的恩考芬尼、西妥昔单抗和mFOLFOX6化疗方案研究
Elena Elez,Takayuki Yoshino,Lin Shen et al.
Elena Elez et al.
Background: First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E-mutated metastatic colorectal cancer, an aggressive ...
Undermining Women's Health Research - Gambling with the Public's Health [0.03%]
破坏女性健康研究 就是在拿公众的健康赌博
Amanda N Kallen,Shannon Whirledge,Kara N Goldman et al.
Amanda N Kallen et al.
Paul S Haber
Paul S Haber
Molly A Bowdring,John Mendelson,Judith J Prochaska
Molly A Bowdring
Alain Braillon,Florian Naudet
Alain Braillon